MONTPELLIER, France–(BUSINESS WIRE)–Feb 21, 2013–Regulatory News: Intrasense (Paris:ALINS) (FR0011179886 – ALINS), a specialist in multimodal medical imaging, today announced that it would fit its platform in 15 hospitals in the USA as part of a clinical trial conducted by a new client, a US manufacturer of medical devices.
Intrasense has sold its Myrian® XP-Lung module, which excels at detecting respiratory pathologies, to a manufacturer of medical devices based in the United States, which is currently conducting a clinical trial subject to approval by the FDA ( Food and Drug Administration ). Myrian® XP-Lung was selected pursuant to an invitation to tender to standardise the assessment of the criteria for inclusion of patients at the 15 investigating centres that are taking part in this clinical trial.
Intrasense is thus continuing to grow on the market for clinical trials and is deploying its product range in the United States.
According to Patrick Mayette, the Chief Executive Officer of Intrasense, “ the deployment of Myrian® XP-Lung as part of this clinical trial will enable us to vindicate our model for growth in the market for clinical trials. Our modular platform, which is already present on the market for monitoring cancer treatment, is also aimed at other medical areas such as pneumonology. The Myrian® platform is not only used by drug companies and CRO to approve new treatments, but also by producers of medical devices for the certification of their products. It can be deployed for centralised reading as well as in the investigating centres in charge of recruiting patients, which enables us to access an extensive and promising market.” About Intrasense : Founded in 2004 based on innovative technology for detecting tissues in scanner imaging, Intrasense designs, develops and markets a unique medical device called Myrian®, a software platform for the visualization and advanced processing of multimodal medical images (MRI, CT scans, PET, X-rays, etc.) Developed with leading academic partners, Myrian® combines and uses all of the various medical images to extract the information that is vital to the patient’s care, to the rapid appraisal of the efficiency of treatment and, therefore, to assessing drug candidates in oncology. Operational on 400 client sites around the world, Myrian® has been certified as a “medical device” in over 40 countries, in the United States (FDA), Europe (CE) and Asia. Intrasense has 50 staff, 22 of whom work in Research & Development. Granted “innovative enterprise” status by OSEO, Intrasense has invested over 8 million euros in R&D since its creation.
For more about Intrasense, please go to www.intrasense.fr